Biography
Dr. Ajay V. Maker M.D. is a surgical oncologist and chief of the UCSF Division of Surgical Oncology. He is an expert in surgically treating complex gastrointestinal and hepatopancreatobiliary diseases (those affecting the liver, pancreas, gallbladder and bile ducts), as well as melanomas and sarcomas.
Maker's research aims to improve early detection of pancreas cancer and to develop new therapies for treating metastases (cancers that have spread from a primary site in the body). Under grants awarded by the Department of Defense and National Institutes of Health (NIH), he works on designing novel immunotherapies (treatments that harness the immune system to fight tumors), particularly for liver metastases from colon cancer. He is one of only a few surgeons to receive the NIH MERIT award and U.S. Army Medical Research Acquisition Activity Cancer Impact Award.
Maker earned his medical degree at Yale School of Medicine. He completed a residency in general surgery at Brigham and Women's Hospital, an affiliate of Harvard Medical School. He trained in surgical oncology at the NIH and completed postdoctoral studies in tumor immunology at the National Cancer Institute; this research included working in trials that led to the Food and Drug Administration approval of Ipilimumab as a new treatment for metastatic melanoma. He later completed a fellowship in surgical oncology at Memorial Sloan Kettering Cancer Center and then gained experience in minimally invasive surgical techniques at the University of Paris. He came to UCSF from his hometown of Chicago, where he was a tenured professor of surgery and of microbiology and immunology at the University of Illinois at Chicago.
In 2015, Maker was the European Society of Surgical Oncology's international traveling fellow and was later honored with the Society of Surgical Oncology's Clinical Investigator Award. He has published more than 170 manuscripts, abstracts and book chapters, and he lectures all over the world. He serves on the editorial boards of many surgical and scientific journals; serves on NIH study sections, which evaluate the merit of proposed research; and has held leadership positions in numerous academic and scientific societies, including program chair of the Americas Hepato-Pancreato-Biliary Association and chair of the Society of Surgical Oncology's gastrointestinal working group. He is also active in various medical societies, including the Surgical Biology Club , Western Surgical Association, American Society of Clinical Oncology and Pancreas Club. He has been named numerous times to Castle Connolly's Top Doctors and Top Doctors for Cancer lists. He is a fellow of the American College of Surgeons and Society of Surgical Oncology.
Research Interests and Funding:
Dr. Maker graduated from Brown University with honors in fine arts and biology, completing his honors thesis in the NASA-funded lab of Dr. Herman Vandenberg in tissue engineering. Thereafter, he enrolled in the Yale School of Medicine and was selected to enter the Basic Science Research Training Fellowship where he was awarded the ADA Medical Scholars Award and the AAS/Novartis Research Award for his work in the R01-funded lab of surgeon Dana Andersen on elucidating mechanisms of pancreatogenic diabetes. He completed his general surgery residency at Harvard University's Brigham and Women's Hospital and a tumor immunology post-doctorate fellowship in the laboratory of Dr. Steven Rosenberg in the Surgery Branch of the NIH/NCI, during which time he was first author on many of the initial phase I/II trials utilizing anti-CTLA4 antibodies. This work was later honored with the "most cited article" award by the Society of Surgical Oncology.
Dr. Maker went on to complete surgical oncology fellowships at the NCI and Memorial Sloan-Kettering Cancer Center, where he continued translational bench research in the Ludwig Cancer Institute, funded, in part, by an ASCO Merit Award and an NCI EDRU U01. He has focused the efforts of his research career on expanding the role of immunotherapy for gastrointestinal tumors and has aligned his clinical practice to coincide with his research interests. His NCI/NIH and DoD-funded research program has identified an immunostimulatory cytokine capable of activating and supporting the proliferation of antigen-specific T-cells to incite an anti-tumor immune response in colorectal liver metastases. This strategy is currently being investigated in combination with oncolytic viruses and immune checkpoint blockade to elicit complete tumor responses. This work has been funded over time as PI by internal funding, the Warren and Clara Cole Foundation of the ACS, the NIH through both K08 and UL1 mechanisms, the DoD (Cancer Impact Award), R37 MERIT from the NCI, and the Society of Surgical Oncology (Investigator of the Year Award).
Dr. Maker's lab also investigates novel drug combinations that stimulate immunogenic cell death and that generate anti-tumor immune responses to treat GI tumor liver metastases. As part of these studies, Dr. Maker has developed multiple unique orthotopic animal models in which to study solid organ metastases that have led to multiple federally funded collaborations, including work on the novel Oncopig porcine large animal cancer model for liver and pancreatic cancer.
Furthermore, Dr. Maker has been a leader in the international IPMN biomarkers research group, and has developed a gene signature to predict malignancy in IPMN from pancreatic cyst fluid. He houses the international IPMN cyst fluid repository, one of the largest biobanks of its kind, for which he serves as the international PI. With this collaborative, he is currently validating a single-platform
biosignature to accurately predict the malignant potential of pancreatic cysts.
Finally, as a clinical surgeon with a passion for developing new laparoscopic and robotic techniques in complex surgical oncology, he has also maintained a robust clinical database from which multiple techniques papers and outcomes studies have been generated along with his residents.
Videos
Education
Institution | Degree | Dept or School | End Date |
---|---|---|---|
Brigham and Women's Hospital/Harvard Medical School | General Surgery | ||
Brown University | Bachelor of Arts | ||
Memorial Sloan-Kettering Cancer Center | Surgical Oncology Fellowship | ||
National Institutes of Health (NIH)/National Cancer Institute (NCI) | Post-doctorate | Tumor Immunology | |
National Institutes of Health (NIH)/National Cancer Institute (NCI), Surgery Branch | Surgical Oncology Fellowship | ||
Yale University School of Medicine | M.D. |
Board Certifications
American Board of Surgery, General Surgery
Clinical Expertise
Pancreatic Cysts including Intraductal Mucinous Neoplasms of the Pancreas (IPMN) and Mucinous Cystic Neoplasms (MCN)
Colorectal Cancer Liver Metastases
Bile Duct Cancer (Cholangiocarcinoma)
Choledochal Cysts
Gallbladder Cancer
Gastrointestinal Carcinoid Tumor
Gastrointestinal Stromal Tumor (GIST)
Liver Cancer (Hepatocellular Carcinoma)
Liver Cysts
Liver Metastases
Melanoma
Minimally Invasive Robotic and Laparoscopic Liver, Pancreas, & Gastrointestinal Surgery
Pancreatic Cancer
Pancreatic Neuroendocrine Tumors
Soft Tissue Sarcomas
Stomach (Gastric) Cancer
Program Affiliations
Surgical Oncology Clinics, including the Gastrointestinal Oncology Clinic, Liver/pancreas/biliary and soft tissue sarcoma/skin cancer clinics: Mission Bay and Parnassus
Hepatobiliary and Pancreas Surgery Program
UCSF Helen Diller Family Comprehensive Cancer Center
Sarcoma Disease Program
Melanoma/Skin Cancer Disease Program
In the News
Grants and Funding
- Stimulating Lymphocyte Activation Combined with Inhibition of Immunosuppressive Signals in Colon Cancer Metastases | NIH | 2020-01-22 - 2024-12-31 | Role: Principal Investigator
- Enhancing anti-tumor immune responses in colon cancer metastases | NIH | 2014-09-17 - 2020-08-31 | Role: Principal Investigator
Research Narrative
Dr. Maker graduated from Brown University with honors in fine arts and biology, completing his honors thesis in the NASA-funded lab of Dr. Herman Vandenberg in tissue engineering. Thereafter, he enrolled in the Yale School of Medicine and was selected to enter the Basic Science Research Training Fellowship where he was awarded the ADA Medical Scholars Award and the AAS/Novartis Research Award for his work in the R01-funded lab of surgeon Dana Andersen on elucidating mechanisms of pancreatogenic diabetes. He completed his general surgery residency at Harvard University’s Brigham and Women’s Hospital and a tumor immunology post-doctorate fellowship in the laboratory of Dr. Steven Rosenberg in the Surgery Branch of the NIH/NCI, during which time he was first author on many of the initial phase I/II trials utilizing anti-CTLA4 antibodies. This work was later honored with the “most cited article” award by the Society of Surgical Oncology.
Dr. Maker went on to complete surgical oncology fellowships at the NCI and Memorial Sloan-Kettering Cancer Center, where he continued translational bench research in the Ludwig Cancer Institute in the labs of Jim Allison and Jed Wolchok, funded, in part, by an ASCO Merit Award and an NCI EDRU U01. He has focused the efforts of his research career on expanding the role of immunotherapy for gastrointestinal tumors and has aligned his clinical practice to coincide with his research interests. His NCI/NIH and DoD-funded research program has identified an immunostimulatory cytokine capable of activating and supporting the proliferation of antigen-specific T-cells to incite an anti-tumor immune response in colorectal liver metastases. This strategy is currently being investigated in combination with oncolytic viruses and immune checkpoint blockade to elicit complete tumor responses. This work has been funded over time as PI by internal funding, the Warren and Clara Cole Foundation of the ACS, the NIH through both K08 and UL1 mechanisms, the DoD (Cancer Impact Award), R37 MERIT from the NCI, and the Society of Surgical Oncology (Investigator of the Year Award).
Dr. Maker's lab also investigates novel drug combinations that stimulate immunogenic cell death and generate anti-tumor immune responses to treat GI tumor liver metastases. As part of these studies, Dr. Maker has developed multiple unique orthotopic animal models in which to study solid organ metastases that has led to multiple federally funded collaborations, including work on the novel Oncopig porcine large animal cancer model for liver and pancreatic cancer.
Furthermore, Dr. Maker has been a leader in the international IPMN biomarkers research group, and has developed a gene signature to predict malignancy in IPMN from pancreatic cyst fluid. He houses the international IPMN cyst fluid repository, one of the largest biobanks of its kind, for which he serves as the international PI. With this collaborative, he is currently validating a single-platform
biosignature to accurately predict the malignant potential of pancreatic cysts.
Finally, as a clinical surgeon with a passion for developing new laparoscopic and robotic techniques in complex surgical oncology, he has also maintained a robust clinical database from which multiple techniques papers and outcomes studies have been generated along with his residents.
Research Interests
Immunotherapies for Cancer
Novel treatments for liver metastases, including colorectal liver metastases
Development of novel immunotherapeutics for metastatic GI cancer, including colorectal liver metastases
Development of biosignatures to guide surgical treatment of pancreatic cancer and pancreatic cysts (IPMN/MCN)
Research Pathways
Publications
- Graft choice in pancreatectomy with vascular resection: equivalent safety in selected patients.| | PubMed
- ASO Author Reflections: Is Adjuvant Therapy Necessary for All Patients with Invasive Mucinous Cystic Neoplasms of the Pancreas? Let's De-escalate.| | PubMed
- ASO Visual Abstract: Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer.| | PubMed
- Distinct Indications for Adjuvant Therapy in Resected Invasive Mucinous Cystic Neoplasms of the Pancreas Compared with Pancreatic Ductal Adenocarcinoma.| | PubMed
- Multi-omic profiling of intraductal papillary neoplasms of the pancreas reveals distinct expression patterns and potential markers of progression.| | PubMed
- The impact of the California state lockdown during the COVID-19 pandemic on management of patients with pancreatic ductal adenocarcinoma.| | PubMed
- Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer.| | PubMed
- Insights on liver-directed surgical innovations, targeted therapies, and immunotherapy for biliary tract cancer: navigating the new European Society for Medical Oncology (ESMO) Clinical Practice Guidelines.| | PubMed
- Pancreas Cyst Diagnosis and Advances in Cyst Fluid Analysis.| | PubMed
- Metastatic melanoma to small bowel: metastasectomy is supported in the era of immunotherapy and checkpoint inhibitors.| | PubMed
- Intraoperative hepatic artery infusion pump perfusion testing with indocyanine green near-infrared imaging offers multiple potential advantages.| | PubMed
- "Mickey Mouse sign" to identify and remove cystic duct stones in postcholecystectomy syndrome.| | PubMed
- Improved survival of patients receiving immunotherapy and chemotherapy following curative-intent resection of colorectal liver metastases.| | PubMed
- Educating Cancer-Associated Fibroblasts (CAFs): Are They the Student or the Teacher?| | PubMed
- Surgical Cancer Care in Safety-Net Hospitals: a Systematic Review.| | PubMed
- Impact of safety-net hospital burden on achievement of textbook oncologic outcomes following resection in for stage I-IV colorectal cancer.| | PubMed
- A Machine Learning Approach to Predict Postoperative Pancreatic Fistula After Pancreaticoduodenectomy Using Only Preoperatively Known Data.| | PubMed
- ASO Visual Abstract: National Practice Patterns in Malignant Peritoneal Mesothelioma-Updates in Management and Survival.| | PubMed
- Non-Canonical Activin A Signaling Stimulates Context-Dependent and Cellular-Specific Outcomes in CRC to Promote Tumor Cell Migration and Immune Tolerance.| | PubMed
- National Practice Patterns in Malignant Peritoneal Mesothelioma: Updates in Management and Survival.| | PubMed
- It is not necessary to resect all mucinous cystic neoplasms of the pancreas: current guidelines do not reflect the actual risk of malignancy.| | PubMed
- Drain Placement After Pancreatic Resection: Friend or Foe For Surgical Site Infections?| | PubMed
- Hypertension Requiring Medication Use: a Silent Predictor of Poor Outcomes After Pancreaticoduodenectomy.| | PubMed
- The Landmark Series: Intraductal Papillary Mucinous Neoplasms of the Pancreas-From Prevalence to Early Cancer Detection.| | PubMed
- Contemporary Trends in Malignant Peritoneal Mesothelioma: Incidence and Survival in the United States.| | PubMed
- Hand-Assisted Versus Pure Minimally-Invasive Distal Pancreatectomy: Is There a Downside to Lending a Hand?| | PubMed
- Minimally Invasive Distal Pancreatectomy Techniques: A Contemporary Analysis Exploring Trends, Similarities, and Differences to Open Surgery.| | PubMed
- The tumour immune microenvironment and microbiome of pancreatic intraductal papillary mucinous neoplasms.| | PubMed
- Diagnostic laparoscopy is underutilized in the staging of gastric adenocarcinoma regardless of hospital type: An US safety net collaborative analysis.| | PubMed
- Physical exam reveals etiology of liver and pancreatic tumors.| | PubMed
- Langer's arch: An anatomic variant complicating axillary node dissection.| | PubMed
- Robotic Surgery for Biliary Tract Cancer.| | PubMed
- LIGHT enhanced bispecific antibody armed T-cells to treat immunotherapy resistant colon cancer.| | PubMed
- Clinical Presentation Patterns and Survival Outcomes of Hispanic Patients With Gastric Cancer.| | PubMed
- Attrition during neoadjuvant chemotherapy for gastric adenocarcinoma is associated with decreased survival: A United States Safety-Net Collaborative analysis.| | PubMed
- The Evolution of Cancer Immunotherapy.| | PubMed
- Is there a difference in utilization of a perioperative treatment approach for gastric cancer between safety net hospitals and tertiary referral centers?| | PubMed
- Race and Gender Differences in Awareness of Colorectal Cancer Screening Tests and Guidelines Among Recently Diagnosed Colon Cancer Patients in an Urban Setting.| | PubMed
- Combining On-Table Embolization with Immediate Resection to Safely Excise Giant Hepatic Hemangiomas.| | PubMed
- Combination Immunotherapy With LIGHT and Interleukin-2 Increases CD8 Central Memory T-Cells In Vivo.| | PubMed
- ASO Author Reflections: How Can We Improve the Postoperative Experience for Our Pancreatic Cancer Patients? A Practical Technique to Optimize Pain Control After Major Abdominal Surgery.| | PubMed
- Surgeon-Placed Continuous Wound Infusion Pain Catheters Markedly Decrease Narcotic Use and Improve Outcomes After Pancreatic Tumor Resection.| | PubMed
- Epidural Analgesia Is Associated with Prolonged Length of Stay After Open HPB Surgery in Over 27,000 Patients.| | PubMed
- Perioperative Broad-spectrum Antibiotics are Associated With Decreased Surgical Site Infections Compared to 1st-3rd Generation Cephalosporins After Open Pancreaticoduodenectomy in Patients With Jaundice or a Biliary Stent.| | PubMed
- Should Drains Suck? A Propensity Score Analysis of Closed-Suction Versus Closed-Gravity Drainage After Pancreatectomy.| | PubMed
- Oncolytic adenovirus encoding LIGHT (TNFSF14) inhibits tumor growth via activating anti-tumor immune responses in 4T1 mouse mammary tumor model in immune competent syngeneic mice.| | PubMed
- Management of Cancer Surgery Cases During the COVID-19 Pandemic: Considerations.| | PubMed
- A propensity score analysis of over 12,000 pancreaticojejunal anastomoses after pancreaticoduodenectomy: does technique impact the clinically relevant fistula rate?| | PubMed
- MADD silencing enhances anti-tumor activity of TRAIL in anaplastic thyroid cancer.| | PubMed
- Cyst Fluid Biosignature to Predict Intraductal Papillary Mucinous Neoplasms of the Pancreas with High Malignant Potential.| | PubMed
- Loss of MADD expression inhibits cellular growth and metastasis in anaplastic thyroid cancer.| | PubMed
- Impact of Immunotherapy after Resection of Pancreatic Cancer.| | PubMed
- Molecular aberrations and signaling cascades implicated in the pathogenesis of anaplastic thyroid cancer.| | PubMed
- Management of asymptomatic, well-differentiated PNETs: results of the Delphi consensus process of the Americas Hepato-Pancreato-Biliary Association.| | PubMed
- Does attending a Delphi consensus conference impact surgeon attitudes? Survey results from the Americas HepatoPancreatoBiliary Association consensus conference on small asymptomatic pancreatic neuroendocrine tumors.| | PubMed
- Therapeutic advances in anaplastic thyroid cancer: a current perspective.| | PubMed
- ASO Author Reflections: Improving Identification of Intraductal Papillary Mucinous Neoplasm Patients at Risk-Current Status and the Role of IPMN Molecular Biomarkers.| | PubMed
- Identification of a Novel OX40L+ Dendritic Cell Subset That Selectively Expands Regulatory T cells.| | PubMed
- KRASG12D and TP53R167H Cooperate to Induce Pancreatic Ductal Adenocarcinoma in Sus scrofa Pigs.| | PubMed
- Vaccination With Mitoxantrone-Treated Primary Colon Cancer Cells Enhances Tumor-Infiltrating Lymphocytes and Clinical Responses in Colorectal Liver Metastases.| | PubMed
- Critical role of OX40 signaling in the TCR-independent phase of human and murine thymic Treg generation.| | PubMed
- What is the Incidence of Malignancy in Resected Intraductal Papillary Mucinous Neoplasms? An Analysis of Over 100 US Institutions in a Single Year.| | PubMed
- Do Drains Contribute to Pancreatic Fistulae? Analysis of over 5000 Pancreatectomy Patients.| | PubMed
- Can we better predict the biologic behavior of incidental IPMN? A comprehensive analysis of molecular diagnostics and biomarkers in intraductal papillary mucinous neoplasms of the pancreas.| | PubMed
- Port-Site Resection in the Surgical Management of Incidental Gallbladder Cancer: A Still Inconclusive Question: A Reply.| | PubMed
- Examining racial disparities in colon cancer clinical delay in the Colon Cancer Patterns of Care in Chicago study.| | PubMed
- The Oncopig Cancer Model: An Innovative Large Animal Translational Oncology Platform.| | PubMed
- PKC-ѳ is dispensable for OX40L-induced TCR-independent Treg proliferation but contributes by enabling IL-2 production from effector T-cells.| | PubMed
- Perioperative management of endocrine insufficiency after total pancreatectomy for neoplasia.| | PubMed
- A Technique to Define Extrahepatic Biliary Anatomy Using Robotic Near-Infrared Fluorescent Cholangiography.| | PubMed
- Targeting cancer with tumor-specific therapeutic strategies-metabolic reprogramming beyond the Warburg effect.| | PubMed
- Mitochondrial protein 18 (MTP18) plays a pro-apoptotic role in chemotherapy-induced gastric cancer cell apoptosis.| | PubMed
- Utilization and impact of adjuvant chemotherapy among patients with resected stage II colon cancer: a multi-institutional analysis.| | PubMed
- LIGHT Elevation Enhances Immune Eradication of Colon Cancer Metastases.| | PubMed
- Isolated Pancreatic Uncinate Duct IPMN.| | PubMed
- Colon cancer cell treatment with rose bengal generates a protective immune response via immunogenic cell death.| | PubMed
- Can Colon Cancer Recurrence and Metastases Be Determined After Surgical Resection Using a Gene Expression Signature?| | PubMed
- Gene-expression profiling to predict responsiveness to immunotherapy.| | PubMed
- Targeting the metabolic pathway of human colon cancer overcomes resistance to TRAIL-induced apoptosis.| | PubMed
- Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer.| | PubMed
- Techniques to perform robotic left adrenalectomy in the obese patient.| | PubMed
- Hepatectomy After Yttrium-90 (Y90) Radioembolization-Induced Liver Fibrosis.| | PubMed
- A Minimally Invasive Technique to Obtain Optimal Tumor Margins in Anatomically Confined Locations Using a Contoured Stapler.| | PubMed
- Precise identification of immunotherapeutic targets for solid malignancies using clues within the tumor microenvironment-Evidence to turn on the LIGHT.| | PubMed
- The Potential of Intralesional Rose Bengal to Stimulate T-Cell Mediated Anti-Tumor Responses.| | PubMed
- Techniques to perform a laparoscopic right adrenalectomy for metastases abutting the liver, renal vein, and posterior vena cava.| | PubMed
- Symptomatic Massive Splenomegaly in Persistent Polyclonal B-cell Lymphocytosis Requiring Splenectomy.| | PubMed
- Tailoring GIST therapy—biology is still king.| | PubMed
- Essential roles of FoxM1 in Ras-induced liver cancer progression and in cancer cells with stem cell features.| | PubMed
- Simultaneous Occurrence of Glandular and Neuroendocrine Components in Lymph Node Metastasis of Gastric MANEC.| | PubMed
- Closure of Melanoma Defects on the Sole of the Foot Using Glaborous Skin: The End of the Flap?| | PubMed
- Operative management of portal annular pancreas during pancreaticoduodenectomy.| | PubMed
- Genetic evidence that intratumoral T-cell proliferation and activation are associated with recurrence and survival in patients with resected colorectal liver metastases.| | PubMed
- Cyst fluid biomarkers for intraductal papillary mucinous neoplasms of the pancreas: a critical review from the international expert meeting on pancreatic branch-duct-intraductal papillary mucinous neoplasms.| | PubMed
- Appendicitis secondary to metastatic melanoma: review of the National Institutes of Health experience.| | PubMed
- Calcifying fibrous tumor of the small intestine associated with Castleman-like lymphadenopathy.| | PubMed
- Dedifferentiated gastrointestinal stromal tumor arising de novo from the small intestine.| | PubMed
- IG20/MADD plays a critical role in glucose-induced insulin secretion.| | PubMed
- Gene expression profiles accurately predict outcome following liver resection in patients with metastatic colorectal cancer.| | PubMed
- Benign adrenal hemangiomas may mimic metastases on PET.| | PubMed
- Management of patients with abdominal malignancy after remote jejunoileal bypass: surgical considerations decades later.| | PubMed
- A technique for laparoendoscopic resection of posterior fundic gastric GISTs without need for a gastrotomy.| | PubMed
- Survival after resection of cutaneous adnexal carcinomas with eccrine differentiation: risk factors and trends in outcomes.| | PubMed
- Shedding LIGHT (TNFSF14) on the tumor microenvironment of colorectal cancer liver metastases.| | PubMed
- MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells.| | PubMed
- Primary hepatic lymphoma presenting as an isolated solitary hepatic cyst.| | PubMed
- Can we predict which residents are going to pass/fail the oral boards?| | PubMed
- Regulatory T cell infiltration predicts outcome following resection of colorectal cancer liver metastases.| | PubMed
- Malignant masquerade of xanthogranulomatous cholecystitis on intraoperative ultrasound of the liver.| | PubMed
- Video: totally laparoscopic left lateral segmentectomy for hepatic malignancies: a modified technique.| | PubMed
- Is port site resection necessary in the surgical management of gallbladder cancer?| | PubMed
- Knockdown of MADD and c-FLIP overcomes resistance to TRAIL-induced apoptosis in ovarian cancer cells.| | PubMed
- Cyst fluid interleukin-1beta (IL1beta) levels predict the risk of carcinoma in intraductal papillary mucinous neoplasms of the pancreas.| | PubMed
- Pancreatic cyst fluid and serum mucin levels predict dysplasia in intraductal papillary mucinous neoplasms of the pancreas.| | PubMed
- Randomized clinical trials in pancreatic adenocarcinoma.| | PubMed
- Novel presentation of a familial pancreatic cancer syndrome.| | PubMed
- Cytology from pancreatic cysts has marginal utility in surgical decision-making.| | PubMed
- Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma.| | PubMed
- Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2.| | PubMed
- Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade.| | PubMed
- Images in cardiothoracic surgery. Active malignant pleural effusion captured through the thoracoscope.| | PubMed
- Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.| | PubMed
- Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.| | PubMed
- Loss of S100 antigenicity in metastatic melanoma.| | PubMed
- Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.| | PubMed
- Rapid acute amiodarone-induced hepatotoxicity in a burn patient.| | PubMed
- Insulin receptor (IR) and glucose transporter 2 (GLUT2) proteins form a complex on the rat hepatocyte membrane.| | PubMed